Journal of Carcinogenesis & Mutagenesis

Mark Frakes

Publications

• Review Article
  EGFR and c-Met Inhibitors are Effective in Reducing Tumorigenicity in Cancer
  Author(s): Amanda Stone, Kymberly Harrington, Mark Frakes, Kory Blank, Supriya Rajanna, Ichwaku Rastogi and Neelu PuriAmanda Stone, Kymberly Harrington, Mark Frakes, Kory Blank, Supriya Rajanna, Ichwaku Rastogi and Neelu Puri
  
  EGFR and c-Met are receptor tyrosine kinases that are implicated in tumor development and progression in several types of cancer. Both EGFR and c-Met, which are known to be overexpressed and mutated in cancer, share common signaling pathways, including the PI3K/ Akt and MAPK pathways. Small molecule tyrosine kinase inhibitors and monoclonal antibodies that work against EGFR and c-Met are at the forefront of cancer therapy, but their individual efficacies are limited due to the development of drug resistance. In recent pre-clinical studies, we observed that combination therapy using mTOR and Wnt inhibitors with EGFR or c-Met tyrosine kinase inhibitors resulted in overcoming drug resistance. Our studies also indicated that EGFR and c-Met tyrosine kinase inhibitor resistance may be due to activation of alternative signaling pathways. The development of additional combinatorial therapies .. View More»
  DOI: 10.4172/2157-2518.1000173

  Abstract PDF